Paul Hammond
Optometrist · Coon Rapids, MNNPI 1285918268
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (40.4%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by GSK at 52.3% of the total. Reporting peaked in 2022 at $7,829 and has fallen 87.2% since, to $1,005 in 2025. Among optometrist clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 53 payments — averaging $272.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$8K
- Thea Pharma Inc.$2K
- Biotissue Holdings Inc.$2K
- AbbVie$1K
- Alcon$1K
- Sight Sciences, Inc.$330
- plus $461 from 6 others
Across 1 payment — averaging $20,978 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Topcon Healthcare, Inc.$21K
What the payments were for
- Consulting fees$2,64018%
- Speaking & faculty fees$5,85040%
- Travel & lodging$3,82926%
- Food & beverage$2,14915%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 6 | $7,563 |
| Thea Pharma Inc. | 5 | $2,060 |
| Biotissue Holdings Inc. | 13 | $1,920 |
| AbbVie(2 entities) | 3 | $1,129 |
| Alcon | 7 | $1,004 |
| Sight Sciences, Inc. | 7 | $330 |
| Sun Pharmaceutical Industries Inc. | 5 | $243 |
| Glaukos Corporation | 3 | $125 |
| Aerie Pharmaceuticals, Inc. | 1 | $46 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $18 |
| Dompe US, Inc. | 1 | $15 |
| Oyster Point Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,468 in reported general payments places this provider in the 95th percentile of 826 optometrist providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 48 | $2,297,050 |
| RestasisCyclosporine | 166 | $205,164 |
| XiidraLifitegrast | 65 | $80,030 |
| RocklatanNetarsudil Mesylat/Latanoprost | 130 | $56,293 |
| LumiganBimatoprost | 119 | $49,560 |
| Cyclosporine | 73 | $42,304 |
| RhopressaNetarsudil Mesylate | 80 | $38,946 |
| XdemvyLotilaner | 13 | $24,361 |
| Latanoprost | 1,218 | $19,609 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 81 | $13,083 |
| VyzultaLatanoprostene Bunod | 32 | $12,230 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 538 | $12,160 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 35 | $8,133 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 30 | $7,465 |
| Travoprost | 25 | $6,574 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $15 | $2,297,05048 claims |
| AbbVieRestasis, Lumigan, Combigan | $1,129 | $258,650298 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $46 | $95,239210 claims |
| AlconSimbrinza | $1,004 | $8,13335 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 826 optometrist providers in Minnesota.
Other optometrist in Coon Rapids
- Jacob LangStillwater$264K
- Britt GustafsonEden Prairie$236K
- Gina WesleyMedina$232K
- Nicholas ColatrellaSartell$84K
- Trevor FossoSartell$45K
- Mathew WalkerAlexandria$43K
- Joshua HanenMinneapolis$40K
- Zachary HollandEdina$36K
- Patrick WellikApple Valley$15K
- Patrick MartinBurnsville$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.